[A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].
A 57-year-old female was diagnosed as local, lung, and multiple liver metastases in the 2 years and 6 months after surgery. As expression of HER2 showed 3+, we performed trastuzumab/paclitaxel combination therapy. After 3 cycles, a rapid complete response was seen clinically. It is suggested that trastuzumab/paclitaxel combination therapy might be a first-line treatment for HER2 overexpressing recurrent breast cancer which had not been treated previously with anthracycline drugs.
Mizuno
Yutaka
Y
Dept. of Surgery, Tohno Kousei Hospital.
Chin
Kakushou
K
Ando
Nobuhisa
N
Oike
Eko
E
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D012074:Remission Induction; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab